Sheera R. Rosenbaum

Sheera R. Rosenbaum

Auto-generated profile, based on publicly available information

Sheera R. Rosenbaum

Affiliation Department of Pharmacology, University of Colorado Anschutz Medical Campus (AMC), Aurora, Colorado, United States of America

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Cell Reports
Verified
Journal Article
Open access
SRSheera R. Rosenbaum
Sheera R. Rosenbaum
MTManoela Tiago
Manoela Tiago
SCSigne Caksa
Signe Caksa
CCClaudia Capparelli
Claudia Capparelli
TPTimothy J. Purwin
Timothy J. Purwin
AAAndrew E. Aplin
Andrew E. Aplin
Developmental factors may regulate the expression of immune modulatory proteins in cancer, linking embryonic development and cancer cell immune evasion. This is particularly relevant in melanoma because immune checkpoint inhibitors are commonly used in the clinic. SRY-box transcription factor 10 (SOX10) mediates neural crest development and is required for melanoma cell growth. In this study, we investigate immune-related targets of SOX10 and observe positive regulation of herpesvirus entry mediator (HVEM) and carcinoembryonic-antigen cell-adhesion molecule 1 (CEACAM1). Sox10 knockout reduces tumor growth in vivo, and this effect is exacerbated in immune-competent models. Modulation of CEACAM1 expression but not HVEM elicits modest effects on tumor growth. Importantly, Sox10 knockout effects on tumor growth are dependent, in part, on CD8+ T cells. Extending this analysis to samples from patients with cutaneous melanoma, we observe a negative correlation with SOX10 and immune-related pathways. These data demonstrate a role for SOX10 in regulating immune checkpoint protein expression and anti-tumor immunity in melanoma.

17 October 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
SRSheera R. Rosenbaum
Sheera R. Rosenbaum
SCSigne Caksa
Signe Caksa
CSCasey D. Stefanski
Casey D. Stefanski
ITIsabella V. Trachtenberg
Isabella V. Trachtenberg
HWHaley P. Wilson
Haley P. Wilson
AAAndrew E. Aplin
Andrew E. Aplin
The transcription factor, SOX10, plays an important role in the differentiation of neural crest precursors to the melanocytic lineage. Malignant transformation of melanocytes leads to the development of melanoma, and SOX10 promotes melanoma cell proliferation and tumor formation. SOX10 expression in melanomas is heterogeneous, and loss of SOX10 causes a phenotypic switch toward an invasive, mesenchymal-like cell state and therapy resistance; hence, strategies to target SOX10-deficient cells are an active area of investigation. The impact of cell state and SOX10 expression on antitumor immunity is not well understood but will likely have important implications for immunotherapeutic interventions. To this end, we tested whether SOX10 status affects the response to CD8+ T cell–mediated killing and T cell–secreted cytokines, TNFα and IFNγ, which are critical effectors in the cytotoxic killing of cancer cells. We observed that genetic ablation of SOX10 rendered melanoma cells more sensitive to CD8+ T cell–mediated killing and cell death induction by either TNFα or IFNγ. Cytokine-mediated cell death in SOX10-deficient cells was associated with features of caspase-dependent pyroptosis, an inflammatory form of cell death that has the potential to increase immune responses. Implications: These data support a role for SOX10 expression altering the response to T cell–mediated cell death and contribute to a broader understanding of the interaction between immune cells and melanoma cells.

24 July 2023 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
AWArthur R Wolin
Arthur R Wolin
MVMelanie Y Vincent
Melanie Y Vincent
THTaylor Hotz
Taylor Hotz
SPStephen C Purdy
Stephen C Purdy
SRSheera R Rosenbaum
Sheera R Rosenbaum
HFHeide L Ford
Heide L Ford
Background: Medulloblastoma is the most common pediatric brain malignancy. Patients with the Group 3 subtype of medulloblastoma (MB) often exhibit MYC amplification and/or overexpression and have the poorest prognosis. While Group 3 MB is known to be highly dependent on MYC, direct targeting of MYC remains elusive. Methods: Patient gene expression data were used to identify highly expressed EYA2 in Group 3 MB samples, assess the correlation between EYA2 and MYC, and examine patient survival. Genetic and pharmacological studies were performed on EYA2 in Group 3 derived MB cell models to assess MYC regulation and viability in vitro and in vivo. Results: EYA2 is more highly expressed in Group 3 MB than other MB subgroups and is essential for Group 3 MB growth in vitro and in vivo. EYA2 regulates MYC expression and protein stability in Group 3 MB, resulting in global alterations of MYC transcription. Inhibition of EYA2 tyrosine phosphatase activity, using a novel small molecule inhibitor (NCGC00249987, or 9987), significantly decreases Group 3 MB MYC expression in both flank and intracranial growth in vivo. Human MB RNA-seq data show that EYA2 and MYC are significantly positively correlated, high EYA2 expression is significantly associated with a MYC transcriptional signature, and patients with high EYA2 and MYC expression have worse prognoses than those that do not express both genes at high levels. Conclusions: Our data demonstrate that EYA2 is a critical regulator of MYC in Group 3 MB and suggest a novel therapeutic avenue to target this highly lethal disease.

9 May 2025 in Science Advances
Verified
Journal Article
Open access
SRSheera R. Rosenbaum
Sheera R. Rosenbaum
CHConnor J. Hughes
Connor J. Hughes
KFKaiah M. Fields
Kaiah M. Fields
SPStephen Connor Purdy
Stephen Connor Purdy
AGAnnika L. Gustafson
Annika L. Gustafson
HFHeide L. Ford
Heide L. Ford
Triple-negative breast cancer cells must evade immune surveillance to metastasize to distant sites, yet this process is not well understood. The Eyes absent (EYA) family of proteins, which are crucial for embryonic development, become dysregulated in cancer, where they have been shown to mediate proliferation, migration, and invasion. Our study reveals an unusual mechanism by which EYA3 reduces the presence of cytotoxic natural killer (NK) cells in the premetastatic niche (PMN) to enhance metastasis, independent of its effects on the primary tumor. We find that EYA3 up-regulates nuclear factor κB signaling to enhance CCL2 expression, which, in contrast to previous findings, suppresses cytotoxic NK cell activation in vitro and their infiltration into the PMN in vivo. These findings uncover an unexpected role for CCL2 in inhibiting NK cell responses at the PMN and suggest that targeting EYA3 could be an effective strategy to reactivate antitumor immune responses to inhibit metastasis.

15 July 2025 in PLOS Biology
Verified
Journal Article
Open access
PDF file
SRSheera R. Rosenbaum
Sheera R. Rosenbaum
KFKaiah M. Fields
Kaiah M. Fields
HFHeide L. Ford
Heide L. Ford
One of the greatest challenges to cancer therapy is tumor cell plasticity. Cancer cells can rapidly alter their phenotype to promote survival and evade immune cell attack, while the plasticity of other cells in the tumor microenvironment (such as immune cells, which need to be able to respond to a diverse range of bodily threats) can be leveraged to further promote tumor growth and progression. This Essay discusses the mutual plasticity of cancer and immune cells, with a focus on epithelial–mesenchymal plasticity in tumor cells, and explores how this interplay contributes to tumor progression and can be targeted therapeutically.

3 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SRSheera R. Rosenbaum
Sheera R. Rosenbaum
CHConnor J. Hughes
Connor J. Hughes
KFKaiah M. Fields
Kaiah M. Fields
SPStephen Connor Purdy
Stephen Connor Purdy
AGAnnika Gustafson
Annika Gustafson
HFHeide L. Ford
Heide L. Ford
Patients with Triple Negative Breast Cancer (TNBC) exhibit high rates of metastases and poor prognoses. The Eyes absent (EYA) family of proteins are developmental transcriptional cofactors/phosphatases that are re-expressed and/or upregulated in numerous cancers. Herein, we demonstrate that EYA3 correlates with decreased survival in breast cancer, and that it strongly, and specifically, regulates metastasis via a novel mechanism that involves NF-kB signaling and an altered innate immune profile at the pre-metastatic niche (PMN). Remarkably, restoration of NF-kB signaling downstream of Eya3 knockdown (KD) restores metastasis without restoring primary tumor growth, isolating EYA3/NF-kB effects to the metastatic site. We show that secreted CCL2, regulated downstream of EYA3/NF-kB, specifically decreases cytotoxic NK cells in the PMN and that re-expression of Ccl2 in Eya3 -KD cells is sufficient to rescue activation/levels of cytotoxic NK cells in vitro and at the PMN, where EYA3-mediated decreases in cytotoxic NK cells are required for metastatic outgrowth. Importantly, analysis of public breast cancer datasets uncovers a significant correlation of EYA3 with NF-kB/CCL2, underscoring the relevance of EYA3/NF-kB/CCL2 to human disease. Our findings suggest that inhibition of EYA3 could be a powerful means to re-activate the innate immune response at the PMN, inhibiting TNBC metastasis. Significance: EYA3 promotes metastasis of TNBC cells by promoting NF-kB-mediated CCL2 expression and inhibiting cytotoxic NK cells at the pre-metastatic niche, highlighting a potential therapeutic target in this subset of breast cancer.